Form 4: 2seventy bio CFO Receives Stock Awards and Options

2seventy bio's Chief Financial Officer, Victoria Eatwell, was granted 108,000 shares of restricted stock and options to purchase 72,000 shares of common stock.

Summary

• Victoria Eatwell, the Chief Financial Officer of 2seventy bio, received a grant of 108,000 shares of restricted stock on January 6, 2025.
• These restricted stock units vest over a four-year period, with the first installment vesting on January 2, 2026.
• Ms. Eatwell also received stock options to purchase 72,000 shares of common stock at an exercise price of $2.64 per share.
• These stock options vest over a four-year period, with 25% vesting on January 2, 2026, and the remainder vesting in 36 equal monthly installments thereafter.
• Both the restricted stock and stock options are subject to Ms. Eatwell's continued service with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The stock and option grants align the CFO's interests with the long-term success of the company.
• The vesting schedules encourage continued service and commitment from the CFO.

Risks

• The value of the stock options is dependent on the future performance of the company's stock price.
• The vesting of the awards is contingent on continued employment, which could be a risk if the CFO leaves the company.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This type of stock and option grant is a common practice for incentivizing and retaining key executives in publicly traded companies, particularly in the biotech sector.

Comparison to Industry Standards

• Stock option and restricted stock grants are standard compensation practices for executives in publicly traded companies, especially in the biotech industry.
• The vesting schedules described are typical for these types of awards, aligning with industry norms for executive retention.
• Companies like Gilead Sciences, Amgen, and Biogen also use similar equity-based compensation to incentivize their executives.

Stakeholder Impact

• The stock and option grants may have a positive impact on shareholder confidence by aligning management's interests with the company's long-term success.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock, executive compensation, insider trading, 2seventy bio, TSVT, CFO, Victoria Eatwell